Back to top
more

Neurocrine Biosciences (NBIX)

(Delayed Data from NSDQ)

$134.97 USD

134.97
496,138

+1.90 (1.43%)

Updated Jun 7, 2024 04:00 PM ET

After-Market: $135.07 +0.10 (0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 248)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for NBIX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Neurocrine Biosciences, Inc. [NBIX]

Reports for Purchase

Showing records 181 - 200 ( 307 total )

Company: Neurocrine Biosciences, Inc.

Industry: Medical - Drugs

Record: 181

06/17/2020

Company Report

Pages: 7

Mechanistic Ponderings Following Announcement of Takeda Psychiatric Collaboration; PT to $131

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Neurocrine Biosciences, Inc.

Industry: Medical - Drugs

Record: 182

06/16/2020

Daily Note

Pages: 4

Let''s Make a Deal; NBIX Expands Into Neuropsych With Takeda

Provider: WEDBUSH SECURITIES INC.

Analyst: CHICO L

Price: 10.00

Research Provided by a Third Party

Company: Neurocrine Biosciences, Inc.

Industry: Medical - Drugs

Record: 183

06/09/2020

Daily Note

Pages: 11

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Neurocrine Biosciences, Inc.

Industry: Medical - Drugs

Record: 184

06/09/2020

Daily Note

Pages: 4

Crinecerfont Continues to Shine in CAH; Reit Buy and $125 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: Neurocrine Biosciences, Inc.

Industry: Medical - Drugs

Record: 185

06/08/2020

Company Report

Pages: 42

Initiating at Outperform, $147 Target; Making The Move into Movement Disorders

Provider: WEDBUSH SECURITIES INC.

Analyst: CHICO L

Price: 100.00

Research Provided by a Third Party

Company: Neurocrine Biosciences, Inc.

Industry: Medical - Drugs

Record: 186

06/08/2020

Daily Note

Pages: 4

Cruising Along In CAH - Crinecerfont Phase 2 Data

Provider: WEDBUSH SECURITIES INC.

Analyst: CHICO L

Price: 10.00

Research Provided by a Third Party

Company: Neurocrine Biosciences, Inc.

Industry: Medical - Drugs

Record: 187

04/03/2020

Industry Report

Pages: 21

Biotechnology - Neurology Prescription Sales Tracker -- Week Ending 3/27/20

Provider: WEDBUSH SECURITIES INC.

Analyst: CHICO L

Price: 75.00

Research Provided by a Third Party

Company: Neurocrine Biosciences, Inc.

Industry: Medical - Drugs

Record: 188

03/20/2020

Daily Note

Pages: 16

Neurology Prescription Sales Tracker -- Week Ending 3/13/20

Provider: WEDBUSH SECURITIES INC.

Analyst: CHICO L

Price: 50.00

Research Provided by a Third Party

Company: Neurocrine Biosciences, Inc.

Industry: Medical - Drugs

Record: 189

03/20/2020

Industry Report

Pages: 16

Neurology Prescription Sales Tracker - Week Ending 3/13/20

Provider: WEDBUSH SECURITIES INC.

Analyst: CHICO L

Price: 50.00

Research Provided by a Third Party

Company: Neurocrine Biosciences, Inc.

Industry: Medical - Drugs

Record: 190

03/13/2020

Industry Report

Pages: 19

Neurology Prescription Sales Tracker -- Week Ending 3/06/20

Provider: WEDBUSH SECURITIES INC.

Analyst: CHICO L

Price: 50.00

Research Provided by a Third Party

Company: Neurocrine Biosciences, Inc.

Industry: Medical - Drugs

Record: 191

02/05/2020

Company Report

Pages: 7

From Ingrezza to 2020 Pivotal Trial Development, Pipeline Lays Foundation for Growth.

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Neurocrine Biosciences, Inc.

Industry: Medical - Drugs

Record: 192

11/05/2019

Company Report

Pages: 7

Continued Ingrezza Momentum Complemented by Progress in PD and CAH Programs

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: Neurocrine Biosciences, Inc.

Industry: Medical - Drugs

Record: 193

07/30/2019

Company Report

Pages: 5

Underlying Business Continues to Outperform as Pipeline and Cash Position Offer Multiple Sources of Upside Optionality

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: Neurocrine Biosciences, Inc.

Industry: Medical - Drugs

Record: 194

04/30/2019

Company Report

Pages: 5

Looking Past Ingrezza Seasonality, We See a Number of Fundamental Drivers of Value Ahead; Reit Buy and $102 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: Neurocrine Biosciences, Inc.

Industry: Medical - Drugs

Record: 195

03/13/2019

Daily Note

Pages: 3

The Positive CAH Interim Data Should Clear the Way for the Regulatory Talk; Reit Buy and $102 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: Neurocrine Biosciences, Inc.

Industry: Medical - Drugs

Record: 196

02/06/2019

Company Report

Pages: 5

As Commercial Advances Continue, Believe CAH Data Can Be Meaningful Catalyst; Reit Buy and $102PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: Neurocrine Biosciences, Inc.

Industry: Medical - Drugs

Record: 197

01/30/2019

Daily Note

Pages: 5

Gene Therapy Is in; Reit Buy and $102 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: Neurocrine Biosciences, Inc.

Industry: Medical - Drugs

Record: 198

01/15/2019

Company Report

Pages: 5

Continue to Believe 2019 Value Proposition Is Attractive; Reit Buy and $102 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: Neurocrine Biosciences, Inc.

Industry: Medical - Drugs

Record: 199

12/13/2018

Company Report

Pages: 5

Our Thoughts Following the Miss in Tourette Syndrome T-Force Gold Trial; Lowering PT to $102

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: Neurocrine Biosciences, Inc.

Industry: Medical - Drugs

Record: 200

11/06/2018

Company Report

Pages: 6

Still a Growth Story; Reit Buy and $162 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party